NAFLD
| 3 min read
Scientists found that the Kisspeptin hormone activates enzymes that stop lipid formation in the mouse liver, suggesting that it has potential as a drug target for treating non-alcoholic fatty liver disease.
| 10+ min read
Through academic, industry, and governmental partnerships, scientists validate and develop non-invasive diagnostics for non-alcoholic fatty liver disease. These tests are set to replace the invasive and risky gold standard: liver biopsy.
| 3 min read
Median Technologies teams up with UC San Diego on diagnosing liver fibrosis severity in NASH patients
| 3 min read
iBiopsy study shows promise in diagnosing severity of disease in patients
| 2 min read
Transcriptome sequencing of patients with liver disease reveals gene expression changes that could help to track disease severity and progression
| 3 min read
Owlstone study pinpoints limonene for early diagnosis of NASH and NAFLD
Page 1 of 1 - 6 Total Items
